Drug Profile
Research programme: analgesic/famotidine fixed combinations - Horizon
Alternative Names: Aspirin/famotidine; HZN-602; HZT-602; HZT-703; Immediate-release naproxen/high-dose famotidine (HZT-602); Naproxen/famotidineLatest Information Update: 26 Apr 2012
Price :
$50
*
At a glance
- Originator Horizon Therapeutics
- Developer Horizon Pharma USA
- Class
- Mechanism of Action Cyclooxygenase inhibitors; Histamine H2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 23 Mar 2012 Discontinued - Preclinical for Pain in USA (PO)
- 01 Apr 2010 Horizon Therapeutics has merged with Nitec Pharma forming Horizon Pharma
- 23 Jul 2007 Preclinical development is ongoing